Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF

被引：0

作者：

Pozniak, A. ^{[1
]}

Maggiolo, F. ^{[2
]}

Podzamczer, D. ^{[3
]}

Yazdanpanah, Y. ^{[4
]}

Gupta, S. ^{[5
]}

Esser, S. ^{[6
]}

Mounzer, K. ^{[7
]}

Grossberg, R. ^{[8
]}

Post, F. ^{[9
]}

Huang, H. ^{[10
]}

Acosta, R. ^{[10
]}

Baeten, J. ^{[10
]}

Hindman, J. ^{[10
]}

Martin, H. ^{[10
]}

Orkin, C. ^{[11
]}

机构：

[1] Chelsea & Westminster Hosp, London, England

[2] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy

[3] Hosp Univ Bellvitge, Lhospitalet De Llobregat, Spain

[4] Hop Bichat Claude Bernard, AP HP, Paris, France

[5] Indiana Univ, Indianapolis, IN 46204 USA

[6] Univ Hosp Essen, Essen, Germany

[7] Univ Penn, Philadelphia FIGHT Perelman Sch Med, Philadelphia, PA 19104 USA

[8] Albert Einstein Coll Med, Bronx, NY 10467 USA

[9] Kings Coll Hosp NHS Fdn Trust, Kings Coll Hosp, London, England

[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[11] Queen Mary Univ London, London, England

来源：

HIV MEDICINE | 2021年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

PE2/68

引用

页码：125 / 125

页数：1

共 50 条

[21] Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study
Lagi, Filippo
Botta, Annarita
Ciccullo, Arturo
Picarelli, Chiara
Fabbiani, Massimiliano
di Giambenedetto, Simona
Borghi, Vanni
Mussini, Cristina
Bartoloni, Alessandro
Sterrantino, Gaetana
HIV RESEARCH & CLINICAL PRACTICE, 2021, 22 (04) : 96 - 101
[22] Early discontinuation of ABC/3TC/DTG and BIC/TAF/FTC single-tablet regimens: a real-life multicentre cohort study
Lagi, F.
Botta, A.
Arturo, C.
Chiara, P.
Fabbiani, M.
Di Giambenedetto, S.
Borghi, V.
Mussini, C.
Bartoloni, A.
Gaetana, S.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 45 - 46
[23] Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE trial
Cossarizza, Andrea
Cozzi-Lepri, Alessandro
Mattioli, Marco
Paolini, Annamaria
Neroni, Anita
De Biasi, Sara
Lo Tartaro, Domenico
Borella, Rebecca
Fidanza, Lucia
Gibellini, Lara
Beghetto, Barbara
Roncaglia, Enrica
Nardini, Giulia
Milic, Jovana
Menozzi, Marianna
Cuomo, Gianluca
Digaetano, Margherita
Orlando, Gabriella
Borghi, Vanni
Guaraldi, Giovanni
Mussini, Cristina
FRONTIERS IN IMMUNOLOGY, 2023, 14
[24] Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) plus F/TAF in treatmentnaive HIV-1 positive adults: Week 48 results
Sax, P. E.
Pozniak, A.
Arribas, J.
Koenig, E.
Dejesus, E.
Stellbrink, H-J
Antinori, A.
Workowski, K.
Slim, J.
Reynes, J.
Garner, W.
Sengupta, D.
Martin, H.
Quirk, E.
Cheng, A.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 121 - 122
[25] Dual therapy with DTG+3TC or DTG+RPV versus triple therapy with B/F/TAF in virologically suppressed adults living with HIV-1: Ummunological outcomes in real-life experience
Troya, J.
Buzon, L.
Pousada, G.
Mican, R.
Galera, C.
Sanz, J.
Santos, I.
Duenas, C.
Cabello, N.
Martin, C.
Galindo, M. J.
Garcinuno, M. A.
Pedrero-Tome, R.
Ortega, D.
Matarranz, M.
HIV MEDICINE, 2023, 24 : 91 - 92
[26] Switching to DTG/3TC fixed-dose combination (FDC) is noninferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks: TANGO study
van Wyk, Jean
Ajana, Faiza
Bisshop, Fiona
De Wit, Stephane
Osiyemi, Olayemi
Portilla, Joaquin
Routy, Jean-Pierre
Wyen, Christoph
Ait-Khaled, Mounir
Nascimento, Maria-Claudia
Pappa, Keith
Wang, Ruolan
Wright, Jonathan
Wynne, Brian
Aboud, Michael
Smith, Kimberly
Rubach, Martin
INFECTION, 2021, 49 (SUPPL 1) : S13 - S13
[27] Low-level HIV replication for DTG/3TC vs TAF-based regimen in TANGO through week 144
Wang, Ruolan
George, Nisha
Ait-Khaled, Mounir
Tomlinson, Andrew
Oyee, James
Lutz, Thomas
Osiyemi, Olayemi
Gorgolas, Miguel
Moodley, Riya
Wynne, Brian
Sithamparanathan, Myooran
Underwood, Mark
Schneider, Martha
HIV MEDICINE, 2023, 24 : 46 - 47
[28] Improved metabolic parameters after switching from TAF-based 3-or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study
van Wyk, J.
Ait-Khaled, M.
Santos, J.
Scholten, S.
Wohlfeiler, M.
Ajana, F.
Jones, B.
Nascimento, M. C.
Tenorio, A.
Smith, D.
Wright, J.
Wynne, B.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 27 - 27
[29] Changes in patient-reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO-DOBLE randomized clinical trial
Garcia-Fraile, Lucio
Masia, Mar
Crusells-Canales, Maria J.
Domingo, Pere
Curran, Adria
Guerri-Fernandez, Roberto
Bernal, Enrique
Bravo, Joaquin
Revollo, Boris
Macias, Juan
Tiraboschi, Juan M.
Montejano Sanchez, Rocio
Amador, Concepcion
Torralba, Miguel
Merino, Dolores
Diaz-Brito, Vicens
Galindo Puerto, Maria J.
Ferra, Sergio
Villoslada, Aroa
Losa, Juan E.
Fanjul, Francisco J.
Perez-Stachowski, Javier
Peraire, Joaquim
Portilla, Joaquin
de la Fuente Moral, Sara
Duenas, Carlos
Vazquez, Maria J.
Di Gregorio, Silvana
Manzanares, Eduardo
Gil, Pedro
de Miguel, Marta
Blanco-Arevalo, Jose Luis
Ryan, Pablo
Alejos, Belen
Martinez, Esteban
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 57 - 58
[30] Antiretroviral treatment in PLWH with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: a real-world cohort analysis
Schuettfort, Gundolf
Cabello, Alfonso
Crusells-Canales, Maria
Hernandez-Mora, Miguel Gorgolas
Hidalgo Tenorio, Carmen
Lopez, Juan
Mican, Rafael
Navarro-Soler, Roser
Negredo, Eugenia
Noe, Sebastian
Puig, Jordi
Rockstroh, Jurgen
Rodriguez, Sergio
Serrao, Rosario
Stephan, Christoph
Torralba, Miguel
Trigo, Diva
Vivancos, Maria
Haberl, Annette
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 68 - 68

← 1 2 3 4 5 →